Niagen Bioscience, Inc. (NAGE)

Nasdaq · Common Stock · Medicinal Chemicals & Botanical Products

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

Corporate structure

10 entities across 7 jurisdictions, 2 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-03-04 — see the exhibit.

Which other public companies file entities in the same places:

Cayman Islands2 Nevada2 Hong Kong2 California1 Netherlands1 United Kingdom1 China1

Subsidiaries of Niagen Bioscience, Inc. as disclosed in its SEC filing
Entity	Jurisdiction	Note
ChromaDex, Inc.	California
ChromaDex International, Inc.	Cayman Islands	offshore centre
ChromaDex Analytics, Inc.	Nevada
ChromaDex Europa B.V.	Netherlands
NAD Pharmaceuticals Corp.	Nevada
ChromaDex UK Limited	United Kingdom
Asia Pacific Scientific, Inc.	Cayman Islands	offshore centre
ChromaDex Asia Limited	Hong Kong
ChromaDex Asia Pacific Ventures Limited	Hong Kong
ChromaDex Trading (Shanghai) Co., Ltd.	China

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

5 / 8

PASSReturn on assets positiveROA 16.3%
PASSOperating cash flow positiveOCF 14M
PASSReturn on assets improving12.5% → 16.3%
FAILCash flow exceeds earningsOCF 14M vs NI 17M
FAILLong-term debt ratio fallingno debt reported
PASSCurrent ratio improving3.57 → 4.86
FAILNo share dilution78M → 85M shares
PASSGross margin improving61.8% → 64.3%
FAILAsset turnover improving1.46× → 1.22×

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$59.3M	−$19.9M	—	59.5%	61,067,000
FY2021	$67.4M	−$27.1M	—	61.5%	67,185,000
FY2022	$72.0M	−$16.5M	—	59.4%	69,729,000
FY2023	$83.6M	−$4.9M	—	60.8%	74,985,000
FY2024	$99.6M	$8.6M	—	61.8%	78,125,000
FY2025	$129.4M	$17.4M	—	64.3%	85,436,000

Ownership flow

11 institutions tracked — 6 added, 5 reduced. Index money added 444,909 shares while active managers cut 1,073,253.

Institutional holders of Niagen Bioscience, Inc. and their share-count change
Manager	Kind	Shares	Change	Value
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	659,584	−669,259	$2.1M
AQR CAPITAL MANAGEMENT LLC	Hedge fund	472,056	−559,279	$1.5M
BlackRock, Inc.	Index	4,184,659	+313,040	$13.3M
GEODE CAPITAL MANAGEMENT, LLC	Index	1,478,603	+133,682	$4.7M
MORGAN STANLEY	Active fund	504,772	+123,683	$1.6M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	97,521	+31,298	$312,000
BANK OF AMERICA CORP /DE/	Active fund	291,727	−12,991	$930,609
FMR LLC	Active fund	31,799	+10,270	$101,440
JPMORGAN CHASE & CO	Active fund	333,204	+6,493	$1.1M
CITADEL ADVISORS LLC	Hedge fund	674,809	−3,468	$2.2M
STATE STREET CORP	Index	1,082,752	−1,813	$3.5M

From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.

Capital returned

What the company actually paid out and bought back, as reported — the record behind any yield figure.

Shares repurchased

2026Q1: $2.4M
2025Q1: $0

Identity

CIK: 0001386570
LEI: 549300I1AHR8KMMFIS52
FIGI: BBG000BG1J71
SIC: 2833 · Medicinal Chemicals & Botanical Products
Incorporated: DE
Headquarters: LOS ANGELES, CA

Ownership

Institutional: 41.5%
Institutions: 187
Insiders: 29.5%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Other medicinal chemicals & botanical products companies

Niagen Bioscience, Inc. files under SIC 2833 — all 8 medicinal chemicals & botanical products companies compared on assets and F-score.

Trulieve Cannabis Corp.TRLV Cronos Group Inc.CRON Canopy Growth CorpCGC Ascend Wellness Holdings, Inc.AAWH USANA HEALTH SCIENCES INCUSNA Jushi Holdings Inc.JUSH

Questions about Niagen Bioscience, Inc.

How many subsidiaries does Niagen Bioscience, Inc. file with the SEC?: 10, listed in its most recent exhibit 21. They are incorporated across 7 jurisdictions, led by California, Cayman Islands, Nevada. 2 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is Niagen Bioscience, Inc. financially healthy?: Niagen Bioscience, Inc. scores 5 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of Niagen Bioscience, Inc.?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BlackRock, Inc. (adding), GEODE CAPITAL MANAGEMENT, LLC (adding), STATE STREET CORP (trimming). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.

Corporate structure

10 entities across 7 jurisdictions, 2 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-03-04 — see the exhibit.

Entity

Jurisdiction

Note

ChromaDex, Inc.

California

ChromaDex International, Inc.

Cayman Islands

offshore centre

ChromaDex Analytics, Inc.

Nevada

ChromaDex Europa B.V.

Netherlands

NAD Pharmaceuticals Corp.

Nevada

ChromaDex UK Limited

United Kingdom

Asia Pacific Scientific, Inc.

Cayman Islands

offshore centre

ChromaDex Asia Limited

Hong Kong

ChromaDex Asia Pacific Ventures Limited

Hong Kong

ChromaDex Trading (Shanghai) Co., Ltd.

China

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

5 / 8

PASSReturn on assets positiveROA 16.3%
PASSOperating cash flow positiveOCF 14M
PASSReturn on assets improving12.5% → 16.3%
FAILCash flow exceeds earningsOCF 14M vs NI 17M
FAILLong-term debt ratio fallingno debt reported
PASSCurrent ratio improving3.57 → 4.86
FAILNo share dilution78M → 85M shares
PASSGross margin improving61.8% → 64.3%
FAILAsset turnover improving1.46× → 1.22×

Year

Revenue

Net income

Free cash flow

Gross margin

FY2020

$59.3M

−$19.9M

—

59.5%

61,067,000

FY2021

$67.4M

−$27.1M

—

61.5%

67,185,000

FY2022

$72.0M

−$16.5M

—

59.4%

69,729,000

FY2023

$83.6M

−$4.9M

—

60.8%

74,985,000

FY2024

$99.6M

$8.6M

—

61.8%

78,125,000

FY2025

$129.4M

$17.4M

—

64.3%

85,436,000

Ownership flow

11 institutions tracked — 6 added, 5 reduced. Index money added 444,909 shares while active managers cut 1,073,253.

Institutional holders of Niagen Bioscience, Inc. and their share-count change
Manager	Kind	Shares	Change	Value
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	659,584	−669,259	$2.1M
AQR CAPITAL MANAGEMENT LLC	Hedge fund	472,056	−559,279	$1.5M
BlackRock, Inc.	Index	4,184,659	+313,040	$13.3M
GEODE CAPITAL MANAGEMENT, LLC	Index	1,478,603	+133,682	$4.7M
MORGAN STANLEY	Active fund	504,772	+123,683	$1.6M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	97,521	+31,298	$312,000
BANK OF AMERICA CORP /DE/	Active fund	291,727	−12,991	$930,609
FMR LLC	Active fund	31,799	+10,270	$101,440
JPMORGAN CHASE & CO	Active fund	333,204	+6,493	$1.1M
CITADEL ADVISORS LLC	Hedge fund	674,809	−3,468	$2.2M
STATE STREET CORP	Index	1,082,752	−1,813	$3.5M

Questions about Niagen Bioscience, Inc.

How many subsidiaries does Niagen Bioscience, Inc. file with the SEC?

10, listed in its most recent exhibit 21. They are incorporated across 7 jurisdictions, led by California, Cayman Islands, Nevada. 2 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.

Is Niagen Bioscience, Inc. financially healthy?

Niagen Bioscience, Inc. scores 5 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of Niagen Bioscience, Inc.?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BlackRock, Inc. (adding), GEODE CAPITAL MANAGEMENT, LLC (adding), STATE STREET CORP (trimming). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.